The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison
Year: 2012
Type: article
Study design: Clinical Trial
Source: Leukemia
DOI: 10.1038/leu.2012.229
Institutions: Cardiff University, Leicester Royal Infirmary, Heartlands Hospital, University Hospital of Wales, Cancer Research UK Clinical Trials Unit, University of Birmingham, Manchester Royal Infirmary, Belfast City Hospital, Queen Alexandra Hospital, Leeds Teaching Hospitals NHS Trust, Nottingham University Hospitals NHS Trust
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: Cancer Research UK
OpenAlex ID: W1994169292
